백신 시장 규모, 점유율과 동향 분석 보고서 : 적응증별, 유형별, 투여 경로별, 연령층별, 유통 채널별, 지역별, 부문 예측(2026-2033년)

Vaccine Market Summary

The global vaccine market size was estimated at USD 72.75 billion in 2025 and is projected to reach USD 115.77 billion by 2033, growing at a CAGR of 5.78% from 2026 to 2033. The market is driven by the increasing investment in R&D and the rising focus of sponsors & investigators on reducing research costs.

Moreover, the increasing adoption of outsourcing laboratory services by pharmaceutical & biotechnology companies and other end users to reduce the overall cost of research activities further supports the market growth over the forecast period. The global vaccine industry is positioned as a strategic component of preventive healthcare systems and is primarily driven by public immunization programs, outbreak preparedness, and routine disease prevention initiatives across regions. Vaccines are integrated into national healthcare budgets and long-term public health planning due to their role in reducing disease burden and downstream treatment costs. According to the World Health Organization, immunization prevents an estimated 2-3 million deaths every year worldwide by protecting against vaccine-preventable diseases such as measles, diphtheria, tetanus, pertussis, and influenza. In April 2024, the WHO published a comprehensive analysis in The Lancet reporting that global immunization programs have prevented approximately 154 million deaths over the past 50 years, reinforcing vaccination as a central public health investment. In April 2025, the World Health Organization marked World Immunization Week with a focus on closing immunization gaps, strengthening immunization delivery systems, and expanding vaccine coverage across the life course, reflecting continued global policy prioritization of immunization as a core public health intervention.

Market growth is supported by the continued prevalence of infectious diseases, expansion of adult and geriatric immunization programs, and recovery of routine vaccination coverage following pandemic-related disruptions. According to the World Health Organization Global Tuberculosis Report 2024, an estimated 10.8 million people developed tuberculosis globally in 2023, with the highest burden concentrated in regions such as Southeast Asia and Africa, sustaining demand for preventive and control strategies in high-burden markets. In April 2024, the World Health Organization Global Hepatitis Report estimated that approximately 254 million people were living with chronic hepatitis B and 50 million with chronic hepatitis C worldwide, with more than 1 million new viral hepatitis infections occurring each year, underscoring the continued public health burden of hepatitis globally. In May 2025, the U.S. Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for older adults aged 65 years and above and for individuals aged 12-64 years with underlying medical conditions, indicating continued regulatory support for vaccine adoption among high-risk populations.

The market is increasingly shaped by shifts in technology platforms, product portfolios, and manufacturing strategies, reflecting a transition toward broader disease coverage and long-term supply resilience. Platform-based development approaches, particularly mRNA technologies, have enabled faster design cycles, greater flexibility in antigen selection, and the development of combination vaccines, supporting portfolio expansion beyond single-disease products. These advancements are contributing to increased focus on respiratory indications and multi-pathogen prevention strategies, particularly within adult and elderly populations. In September 2022, Pfizer and BioNTech initiated Phase III clinical trials for an mRNA-based influenza vaccine, marking the extension of mRNA platforms beyond COVID-19 applications. In May 2025, the World Health Organization reported that its mRNA Technology Transfer Programme had expanded to 15 global partners, supporting the decentralization of vaccine manufacturing and the development of regional production capacity. In parallel, expanding adult immunization frameworks and broader regulatory recommendations are increasing the addressable market for vaccines across age groups, indicating that market evolution is being driven by public-sector priorities, platform diversification, and demographic shifts rather than short-term demand fluctuations.

Global Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vaccine market report based on indication, type, route of administration, age group, distribution channel, and region:

• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Viral Vaccines
  • Hepatitis
  • Pediatric (Children)
  • Adult
  • Influenza
  • Pediatric (Children)
  • Adult
  • HPV
  • Pediatric (Children)
  • Adult
  • MMR
  • Pediatric (Children)
  • Adult
  • Rotavirus
  • Pediatric (Children)
  • Adult
  • Herpes Zoster
  • Pediatric (Children)
  • Adult
  • Japanese Encephalitis
  • Pediatric (Children)
  • Adult
  • RSV
  • Pediatric (Children)
  • Adult
  • Others
  • Pediatric (Children)
  • Adult
• Bacterial Vaccines
  • Meningococcal Diseases
  • Pediatric (Children)
  • Adult
  • Pneumococcal diseases
  • Pediatric (Children)
  • Adult
  • DPT
  • Pediatric (Children)
  • Adult
  • Others
  • Pediatric (Children)
  • Adult
• Cancer Vaccines
  • Pediatric (Children)
  • Adult
• Allergy Vaccines
  • Pediatric (Children)
  • Adult
• Other
  • Pediatric (Children)
  • Adult
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Subunit Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines
  • Toxoid Vaccines
• Inactivated
• Live Attenuated
• mRNA Vaccines
• Viral Vector Vaccines
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Parenteral
• Nasal
• Age Group Outlook (Revenue, USD Million, 2021 - 2033)
• Pediatric
• Adult
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital & Retail Pharmacies
• Government Suppliers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1 Market Segmentation & Scope
• 1.2 Segment Definitions
  • 1.2.1 Indication
  • 1.2.2 Type
  • 1.2.3 Route of Administration
  • 1.2.4 Age Group
  • 1.2.5 Distribution Channel
• 1.3 Estimates and Forecast Timeline
• 1.4 Research Methodology
• 1.5 Information Procurement
  • 1.5.1 Purchased Database
  • 1.5.2 GVR's Internal Database
  • 1.5.3 Secondary Sources
  • 1.5.4 Primary Research
• 1.6 Information Analysis
  • 1.6.1 Data Analysis Models
• 1.7 Market Formulation & Data Visualization
• 1.8 Model Details
  • 1.8.1 Commodity Flow Analysis
• 1.9 List of Secondary Sources
• 1.10 Objectives

Chapter 2. Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3. Vaccine Market Variables, Trends, & Scope

• 3.1 Market Lineage Outlook
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
  • 3.2.2 Market Restraint Analysis
• 3.3 Business Environment Analysis
  • 3.3.1 Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1 Supplier Power
    • 3.3.1.2 Buyer Power
    • 3.3.1.3 Substitution Threat
    • 3.3.1.4 Threat of New Entrants
    • 3.3.1.5 Competitive Rivalry
  • 3.3.2 PESTLE Analysis
  • 3.3.3 Pipeline Analysis
  • 3.3.4 Patent Expiry Analysis
  • 3.3.5 Pricing Analysis

Chapter 4. Vaccine Market: Indication Business Analysis

• 4.1. Indication Market Share, 2025 & 2033
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 4.4. Viral Vaccines
  • 4.4.1 Viral Vaccine Market, 2021 - 2033 (USD Million)
    • 4.4.1.1 Hepatitis Market, 2021 - 2033 (USD Million)
      • 4.4.1.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.4.1.1.2 Adult Market, 2021 - 2033 (USD Million)
    • 4.4.1.2 Influenza Market, 2021 - 2033 (USD Million)
      • 4.4.1.2.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.4.1.2.2 Adult Market, 2021 - 2033 (USD Million)
    • 4.4.1.3 HPV Market, 2021 - 2033 (USD Million)
      • 4.4.1.3.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.4.1.3.2 Adult Market, 2021 - 2033 (USD Million)
    • 4.4.1.4 MMR Market, 2021 - 2033 (USD Million)
      • 4.4.1.4.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.4.1.4.2 Adult Market, 2021 - 2033 (USD Million)
    • 4.4.1.5 Rotavirus Market, 2021 - 2033 (USD Million)
      • 4.4.1.5.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.4.1.5.2 Adult Market, 2021 - 2033 (USD Million)
    • 4.4.1.6 Herpes Zoster Market, 2021 - 2033 (USD Million)
      • 4.4.1.6.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.4.1.6.2 Adult Market, 2021 - 2033 (USD Million)
    • 4.4.1.7 Japanese Encephalitis Market, 2021 - 2033 (USD Million)
      • 4.4.1.7.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.4.1.7.2 Adult Market, 2021 - 2033 (USD Million)
    • 4.4.1.8 RSV Market, 2021 - 2033 (USD Million)
      • 4.4.1.8.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.4.1.8.2 Adult Market, 2021 - 2033 (USD Million)
    • 4.4.1.9 Others Market, 2021 - 2033 (USD Million)
      • 4.4.1.9.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.4.1.9.2 Adult Market, 2021 - 2033 (USD Million)
• 4.5. Bacterial Vaccines
  • 4.5.1 Bacterial Vaccine Market, 2021 - 2033 (USD Million)
    • 4.5.1.1 Meningococcal Diseases Market, 2021 - 2033 (USD Million)
    • 4.5.1.2 Pneumococcal diseases Market, 2021 - 2033 (USD Million)
    • 4.5.1.3 DPT Market, 2021 - 2033 (USD Million)
    • 4.5.1.4 Others Market, 2021 - 2033 (USD Million)
• 4.6. Cancer Vaccines
  • 4.6.1 Cancer Vaccine Market, 2021 - 2033 (USD Million)
    • 4.6.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    • 4.6.1.2 Adult Market, 2021 - 2033 (USD Million)
• 4.7. Allergy Vaccines
  • 4.7.1 Allergy Vaccine Market, 2021 - 2033 (USD Million)
    • 4.7.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    • 4.7.1.2 Adult Market, 2021 - 2033 (USD Million)
• 4.8. Other
  • 4.8.1 Other Market, 2021 - 2033 (USD Million)
    • 4.8.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    • 4.8.1.2 Adult Market, 2021 - 2033 (USD Million)

Chapter 5. Vaccine Market: Type Business Analysis

• 5.1. Type Market Share, 2025 & 2033
• 5.2. Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 5.4. Subunit Vaccines
  • 5.4.1 Subunit Vaccine Market, 2021 - 2033 (USD Million)
    • 5.4.1.1 Recombinant Vaccine Market, 2021 - 2033 (USD Million)
    • 5.4.1.2 Conjugate Vaccine Market, 2021 - 2033 (USD Million)
    • 5.4.1.3 Toxoid Vaccine Market, 2021 - 2033 (USD Million)
• 5.5. Inactivated
  • 5.5.1 Inactivated Market, 2021 - 2033 (USD Million)
• 5.6. Live Attenuated
  • 5.6.1 Live Attenuated Market, 2021 - 2033 (USD Million)
• 5.7. mRNA Vaccines
  • 5.7.1 mRNA Vaccine Market, 2021 - 2033 (USD Million)
• 5.8. Viral Vector Vaccines
  • 5.8.1 Viral Vector Vaccine Market, 2021 - 2033 (USD Million)

Chapter 6. Vaccine Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2033
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
• 6.4. Oral
  • 6.4.1 Oral Market, 2021 - 2033 (USD Million)
• 6.5. Parenteral
  • 6.5.1 Parenteral Market, 2021 - 2033 (USD Million)
• 6.6. Nasal
  • 6.6.1 Nasal Market, 2021 - 2033 (USD Million)

Chapter 7. Vaccine Market: Age Group Business Analysis

• 7.1. Age Group Market Share, 2025 & 2033
• 7.2. Age Group Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Million)
• 7.4. Pediatric
  • 7.4.1 Pediatric Market, 2021 - 2033 (USD Million)
• 7.5. Adult
  • 7.5.1 Adult Market, 2021 - 2033 (USD Million)

Chapter 8. Vaccine Market: Distribution Channel Business Analysis

• 8.1. Distribution Channel Market Share, 2025 & 2033
• 8.2. Distribution Channel Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 8.4. Hospital & Retail Pharmacies
• 8.5. Government Suppliers
  • 8.5.1 Government Suppliers Market, 2021 - 2033 (USD Million)
• 8.6. Others
  • 8.6.1 Others Market, 2021 - 2033 (USD Million)

Chapter 9. Vaccine Market: Regional Estimates & Trend Analysis

• 9.1 Regional Market Share Analysis, 2025 & 2033
• 9.2 Regional Market Dashboard
• 9.3 Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 9.4 North America
  • 9.4.1 North America Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 9.4.2 U.S.
    • 9.4.2.1 Key Country Dynamics
    • 9.4.2.2 Regulatory Framework
    • 9.4.2.3 Pricing Analysis
    • 9.4.2.4 U.S. Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3 Canada
    • 9.4.3.1 Key Country Dynamics
    • 9.4.3.2 Regulatory Framework
    • 9.4.3.3 Pricing Analysis
    • 9.4.3.4 Canada Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4 Mexico
    • 9.4.4.1 Key Country Dynamics
    • 9.4.4.2 Regulatory Framework
    • 9.4.4.3 Pricing Analysis
    • 9.4.4.4 Mexico Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5 Europe
  • 9.5.1 Europe Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 9.5.2 UK
    • 9.5.2.1 Key Country Dynamics
    • 9.5.2.2 Regulatory Framework
    • 9.5.2.3 Pricing Analysis
    • 9.5.2.4 UK Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3 Germany
    • 9.5.3.1 Key Country Dynamics
    • 9.5.3.2 Regulatory Framework
    • 9.5.3.3 Pricing Analysis
    • 9.5.3.4 Germany Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4 France
    • 9.5.4.1 Key Country Dynamics
    • 9.5.4.2 Regulatory Framework
    • 9.5.4.3 Pricing Analysis
    • 9.5.4.4 France Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5 Italy
    • 9.5.5.1 Key Country Dynamics
    • 9.5.5.2 Regulatory Framework
    • 9.5.5.3 Pricing Analysis
    • 9.5.5.4 Italy Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6 Spain
    • 9.5.6.1 Key Country Dynamics
    • 9.5.6.2 Regulatory Framework
    • 9.5.6.3 Pricing Analysis
    • 9.5.6.4 Spain Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7 Denmark
    • 9.5.7.1 Key Country Dynamics
    • 9.5.7.2 Regulatory Framework
    • 9.5.7.3 Pricing Analysis
    • 9.5.7.4 Denmark Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.8 Norway
    • 9.5.8.1 Key Country Dynamics
    • 9.5.8.2 Regulatory Framework
    • 9.5.8.3 Pricing Analysis
    • 9.5.8.4 Norway Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.9 Sweden
    • 9.5.9.1 Key Country Dynamics
    • 9.5.9.2 Regulatory Framework
    • 9.5.9.3 Pricing Analysis
    • 9.5.9.4 Sweden Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6 Asia Pacific
  • 9.6.1 Asia Pacific Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 9.6.2 Japan
    • 9.6.2.1 Key Country Dynamics
    • 9.6.2.2 Regulatory Framework
    • 9.6.2.3 Pricing Analysis
    • 9.6.2.4 Japan Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3 China
    • 9.6.3.1 Key Country Dynamics
    • 9.6.3.2 Regulatory Framework
    • 9.6.3.3 Pricing Analysis
    • 9.6.3.4 China Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.4 India
    • 9.6.4.1 Key Country Dynamics
    • 9.6.4.2 Regulatory Framework
    • 9.6.4.3 Pricing Analysis
    • 9.6.4.4 India Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.5 South Korea
    • 9.6.5.1 Key Country Dynamics
    • 9.6.5.2 Regulatory Framework
    • 9.6.5.3 Pricing Analysis
    • 9.6.5.4 South Korea Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.6 Australia
    • 9.6.6.1 Key Country Dynamics
    • 9.6.6.2 Regulatory Framework
    • 9.6.6.3 Pricing Analysis
    • 9.6.6.4 Australia Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.7 Thailand
    • 9.6.7.1 Key Country Dynamics
    • 9.6.7.2 Regulatory Framework
    • 9.6.7.3 Pricing Analysis
    • 9.6.7.4 Thailand Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7 Latin America
  • 9.7.1 Latin America Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 9.7.2 Brazil
    • 9.7.2.1 Key Country Dynamics
    • 9.7.2.2 Regulatory Framework
    • 9.7.2.3 Pricing Analysis
    • 9.7.2.4 Brazil Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3 Argentina
    • 9.7.3.1 Key Country Dynamics
    • 9.7.3.2 Regulatory Framework
    • 9.7.3.3 Pricing Analysis
    • 9.7.3.4 Argentina Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.8 Middle East & Africa
  • 9.8.1 Middle East & Africa Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 9.8.2 South Africa
    • 9.8.2.1 Key Country Dynamics
    • 9.8.2.2 Regulatory Framework
    • 9.8.2.3 Pricing Analysis
    • 9.8.2.4 South Africa Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.3 Saudi Arabia
    • 9.8.3.1 Key Country Dynamics
    • 9.8.3.2 Regulatory Framework
    • 9.8.3.3 Pricing Analysis
    • 9.8.3.4 Saudi Arabia Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.4 UAE
    • 9.8.4.1 Key Country Dynamics
    • 9.8.4.2 Regulatory Framework
    • 9.8.4.3 Pricing Analysis
    • 9.8.4.4 UAE Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.5 Kuwait
    • 9.8.5.1 Key Country Dynamics
    • 9.8.5.2 Regulatory Framework
    • 9.8.5.3 Pricing Analysis
    • 9.8.5.4 Kuwait Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1 Serum Institute of India Pvt. Ltd.
    • 10.5.1.1 Overview
    • 10.5.1.2 Financial Performance
    • 10.5.1.3 Application Benchmarking
    • 10.5.1.4 Strategic Initiatives
  • 10.5.2 Seqirus
    • 10.5.2.1 Overview
    • 10.5.2.2 Financial Performance
    • 10.5.2.3 Application Benchmarking
    • 10.5.2.4 Strategic Initiatives
  • 10.5.3 Sanofi
    • 10.5.3.1 Overview
    • 10.5.3.2 Financial Performance
    • 10.5.3.3 Application Benchmarking
    • 10.5.3.4 Strategic Initiatives
  • 10.5.4 Merck & Co., Inc.
    • 10.5.4.1 Overview
    • 10.5.4.2 Financial Performance
    • 10.5.4.3 Application Benchmarking
    • 10.5.4.4 Strategic Initiatives
  • 10.5.5 Pfizer Inc.
    • 10.5.5.1 Overview
    • 10.5.5.2 Financial Performance
    • 10.5.5.3 Application Benchmarking
    • 10.5.5.4 Strategic Initiatives
  • 10.5.6 Moderna Inc.
    • 10.5.6.1 Overview
    • 10.5.6.2 Financial Performance
    • 10.5.6.3 Application Benchmarking
    • 10.5.6.4 Strategic Initiatives
  • 10.5.7 Sinovac
    • 10.5.7.1 Overview
    • 10.5.7.2 Financial Performance
    • 10.5.7.3 Application Benchmarking
    • 10.5.7.4 Strategic Initiatives
  • 10.5.8 BioNTech SE
    • 10.5.8.1 Overview
    • 10.5.8.2 Financial Performance
    • 10.5.8.3 Application Benchmarking
    • 10.5.8.4 Strategic Initiatives
  • 10.5.9 AstraZeneca
    • 10.5.9.1 Overview
    • 10.5.9.2 Financial Performance
    • 10.5.9.3 Application Benchmarking
    • 10.5.9.4 Strategic Initiatives